Pharvaris N : SUBSCRIPTION AGREEMENT - Form 6-K
SUBSCRIPTION AGREEMENT Pharvaris N.V. Emmy Noetherweg 2 2333 BK Leiden The Netherlands Ladies and Gentlemen: ... | June 20, 2023
Source: marketscreener.com
Richard Gaster News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Richard Gaster. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Richard Gaster Today - Breaking & Trending Today
Entact Bio Launches with $81 Million Series A to Develop Precision Medicines for Targeted Protein En
Launch fueled by syndicate of blue-chip investors co-led by Qiming Venture Partners USA and venBio PartnersCompany’s proprietary end-to-end Encompass™ platform designs enhancement-targeting chimeric (ENTAC™) moleculesFounding team comprised of world-class scientific leadersWATERTOWN, Mass.--(BUSINESS WIRE)--Entact B...
Source: pharmiweb.com
ImmPACT Bio Closes $111 Million Series B Financing, Names New Board Chair and New President and CEO, and Updates on Phase 1 Clinical Study in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
/PRNewswire/ -- ImmPACT Bio USA, Inc. ("ImmPACT Bio"), a clinical-stage company developing transformative logic-gate based chimeric antigen receptor (CAR)...
Source: prnewswire.com
ImmPACT Bio Closes $111 Million Series B Financing, Names New Board Chair and New President and CEO, and Updates on Phase 1 Clinical Study in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
/PRNewswire/ -- ImmPACT Bio USA, Inc. ("ImmPACT Bio"), a clinical-stage company developing transformative logic-gate based chimeric antigen receptor (CAR)...
Source: prnewswire.com
Follow the Money: AI-Powered Drug Discovery, Remote Access Labs
July 1, 2021 July 1, 2021 | Insilico Medicine closes a Series C for AI-powered drug discovery, while other investments fuel remote access labs, natural products, high throughput screening, and more. $550M: VC Fund for Therapeutics for Unmet Needs venBio has announced the closing of venBio Global Strategic Fund IV, LP (“venBio Fund IV”), its fourth life sciences venture capital fund, exceeding its target and closing on approximately $550 million in capital commitments in an oversubscribed fundraise. The capital was raised from existing and new investors, including a broad rang...
Source: bio-itworld.com